NF-kB Inhibitors

NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a transcription factor that was discovered in 1986 by Dr. David Baltimore and colleagues.  Today, NF-kB is known to have key roles in the innate and adaptive immune responses as well as a number of other cellular processes.  However, aberrant activation of the NF-kB pathway mediates a broad spectrum of diseases including cancer, inflammation and viral infections.  Profectus has discovered several series of small molecule inhibitors that directly inhibit the binding of NF-kB components, p65 (RelA), RelB and c-Rel to DNA.  As a result, our proprietary compounds can block both the canonical and the non-canonical paths of NF-kB.  The dual inhibition is distinct from IkBb kinase inhibitors that affect only the canonical path.  We have demonstrated the efficacy of the PBS compounds in animal models of multiple myeloma and rheumatoid arthritis.  We are seeking drug development partners to unlock the potential of our NF-kB inhibitors as cancer chemotherapeutics, anti-inflammatory agents and treatments for viral diseases.

Learn More Profectus NF-kB inhibitors >